📊 ELUT Key Takeaways
Is Elutia Inc.. (ELUT) a Good Investment?
Elutia faces critical fundamental challenges: revenue is declining 15% YoY while operating losses remain severe at -$6.3M on a $3.1M revenue base. Negative operating cash flow of -$7.8M creates a ~3.4 year cash runway, exacerbated by 1.16x debt/equity leverage and inability to cover interest from operations (coverage ratio: -4.8x).
Elutia's core fundamentals are weak: revenue declined 15% year over year, operating margin was deeply negative at -218.9%, and free cash flow was severely negative, indicating poor growth quality and an unsustainable earnings profile. The large net income appears disconnected from operating performance, suggesting a likely non-recurring benefit rather than a true improvement in the underlying business. While liquidity is currently supported by a solid cash balance and acceptable current ratio, persistent operating losses and cash burn materially weaken financial health.
Elutia Inc.. Key Strengths (ELUT)
- Strong gross margin of 57.9% indicates underlying product value and pricing power
- Current liquidity position adequate with $28.5M cash and 2.05x current ratio providing near-term stability
- Biological products sector suggests potential for high-value pipeline despite early commercialization stage
- Gross margin of 53.7% suggests the company still has some underlying product-level economic value
- Cash and equivalents of $36.35M provide near-term liquidity support
- Current ratio of 2.22x and quick ratio of 2.12x indicate manageable short-term obligations
ELUT Stock Risks: Elutia Inc.. Investment Risks
- Revenue declining 15% YoY signals market adoption challenges or loss of product competitiveness
- Unsustainable operating losses (-$6.3M) with -203.9% operating margin on small revenue base
- Negative operating cash flow (-$7.8M) with approximately 3.4 year cash runway at current burn rate without profitability inflection
- High leverage (1.16x Debt/Equity) with negative interest coverage (-4.8x); cannot service debt from operational earnings
- Negative returns destroying shareholder value (ROE: -33.2%, ROA: -13.5%)
- Revenue fell 15.0% year over year, pointing to weak commercial momentum
- Operating loss of $26.91M and free cash flow of -$46.69M indicate severe cash burn and poor earnings quality
- Leverage is meaningful relative to equity, and negative interest coverage reflects weak debt-servicing capacity from operations
Key Metrics to Watch
- Quarterly revenue trajectory - must stabilize and inflect positive to avoid cash depletion scenario
- Operating expense reduction pathway - survival dependent on clear path to profitability before cash exhaustion
- Cash burn rate and runway - core survival metric for pre-profitable stage company
- Gross margin sustainability - whether 57.9% margin is maintainable as operations scale
- Revenue growth and gross profit trend
- Operating cash flow and free cash flow burn rate
Elutia Inc.. (ELUT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.05x current ratio provides a solid financial cushion.
ELUT Profit Margin, ROE & Profitability Analysis
ELUT vs Healthcare Sector: How Elutia Inc.. Compares
How Elutia Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Elutia Inc.. Stock Overvalued? ELUT Valuation Analysis 2026
Based on fundamental analysis, Elutia Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Elutia Inc.. Balance Sheet: ELUT Debt, Cash & Liquidity
ELUT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Elutia Inc..'s revenue has declined by 69% over the 5-year period, indicating business contraction. The most recent EPS of $-1.86 indicates the company is currently unprofitable.
ELUT Revenue Growth, EPS Growth & YoY Performance
ELUT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.0M | -$3.9M | $-0.17 |
| Q3 2025 | $3.3M | $1.3M | $-0.19 |
| Q2 2025 | $6.3M | -$9.6M | $-0.26 |
| Q1 2025 | $6.0M | -$3.9M | $-0.21 |
| Q3 2024 | $5.9M | $1.3M | $-0.33 |
| Q2 2024 | $6.3M | -$10.6M | $-0.65 |
| Q3 2023 | $5.8M | -$8.0M | $-0.49 |
| Q2 2023 | $10.3M | -$9.4M | $-0.65 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Elutia Inc.. Dividends, Buybacks & Capital Allocation
ELUT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Elutia Inc.. (CIK: 0001708527)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELUT
What is the AI rating for ELUT?
Elutia Inc.. (ELUT) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 83% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELUT's key strengths?
Claude: Strong gross margin of 57.9% indicates underlying product value and pricing power. Current liquidity position adequate with $28.5M cash and 2.05x current ratio providing near-term stability. ChatGPT: Gross margin of 53.7% suggests the company still has some underlying product-level economic value. Cash and equivalents of $36.35M provide near-term liquidity support.
What are the risks of investing in ELUT?
Claude: Revenue declining 15% YoY signals market adoption challenges or loss of product competitiveness. Unsustainable operating losses (-$6.3M) with -203.9% operating margin on small revenue base. ChatGPT: Revenue fell 15.0% year over year, pointing to weak commercial momentum. Operating loss of $26.91M and free cash flow of -$46.69M indicate severe cash burn and poor earnings quality.
What is ELUT's revenue and growth?
Elutia Inc.. reported revenue of $3.1M.
Does ELUT pay dividends?
Elutia Inc.. does not currently pay dividends.
Where can I find ELUT SEC filings?
Official SEC filings for Elutia Inc.. (CIK: 0001708527) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELUT's EPS?
Elutia Inc.. has a diluted EPS of $-0.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ELUT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Elutia Inc.. has a C grade with 83% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ELUT stock overvalued or undervalued?
Valuation metrics for ELUT: ROE of -33.2% (sector avg: 15%), net margin of -239.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ELUT's AI grade for 2026?
Our dual AI analysis gives Elutia Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELUT's free cash flow?
Elutia Inc..'s operating cash flow is $-7.8M, with capital expenditures of $459.0K. FCF margin is -266.2%.
How does ELUT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -239.9% (avg: 12%), ROE -33.2% (avg: 15%), current ratio 2.05 (avg: 2).